India's Center for Disease Biology to collaborate with ICMR in diabetes
This article was originally published in Scrip
India's Center for Disease Biology expects to work closely with the Indian Council of Medical Research (ICMR), the country's apex body for the formulation, co-ordination and promotion of biomedical research, and it laboratories in the area of diabetes.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.